The WHO Global Traditional Medicine Centre convened technical experts from all six WHO regions in Hong Kong SAR (China) between 16 and 18 November 2026. The meeting lasted three days. It continued a sequence of online and in-person sessions WHO has held since November 2024 to prepare the first volume of international quality standards for herbal medicines. Participants aimed to move the draft work forward and resolve issues around structure and content for the planned monographs.
Attendance reflected broad geographic representation. The study team reported that the meeting was intended to refine the scope of the publication, and to advance the scientific approach to monograph development. WHO described the initiative as an effort to harmonize quality assurance and regulatory guidance across jurisdictions that use traditional herbal products.
Experts discussed how each monograph will be organised, and the meeting included a proposal for a dedicated section in every monograph on biodiversity, traditional knowledge and sustainable use. The panel considered technical content and editorial structure; data indicated members debated the balance between scientific quality-assurance elements and contextual material about biodiversity and traditional practice.
WHO stated the first planned volume will include 12 monographs on priority herbal medicines. The source did not provide further methodological details for monograph development, nor did it specify analytical methods, reference standards, or criteria for selecting the 12 priority items. Those operational elements remain subject to the WHO-led drafting and review process.
Dr Kim Sungchol, Unit Head, Traditional Medicine Norms, Standards and Systems Integration Unit at the WHO GTMC, delivered opening remarks on behalf of the Centre Director. He said that quality standards are fundamental to building confidence in traditional medicine. The meeting agenda, as reported, emphasised quality assurance and regulatory capacity as core objectives.
Mr Liu Jinfeng, Vice Minister of the National Health Commission and Commissioner of the National Administration of Traditional Chinese Medicine, contributed a pre-recorded message. He framed traditional medicine as complementary to biomedicine and urged scientific, evidence-based approaches, openness, collaboration and people-centred guidance. Dr Ronald Lam, Director of Health of the Government of the Hong Kong Special Administrative Region, said the forum provided a platform for expert exchange on greater consistency in the quality of herbal medicines.
The meeting conveners reported that discussions aimed to produce practical guidance that regulators and health systems can use when evaluating, assuring and integrating evidence-informed traditional medicine.
WHO formally thanked the Department of Health of the Hong Kong Special Administrative Region for hosting the third in-person meeting for this initiative. The agency also acknowledged substantial technical contributions from the WHO Collaborating Centre for Traditional Medicine at the Department of Health, Hong Kong SAR Government, and from the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H), Ministry of Ayush, Government of India.
These collaborator acknowledgements reflect the multi-institutional technical inputs feeding into the monograph drafting process. The source material notes collaboration and contribution, but does not itemise specific deliverables or the exact nature of each institution’s technical input.
WHO placed the work within the framework of the WHO Global Traditional Medicine Strategy 2025–2034. According to the report, the initiative supports objectives to strengthen quality assurance and regulatory systems, and to promote safe, evidence-informed use of traditional medicine within health systems. The agency presented the monograph series as a step toward regulatory convergence and improved confidence in product quality.
The announcement does not detail implementation pathways, nor does it specify how member states will incorporate the standards into national regulations or pharmacopoeias. Such implementation activities are expected to derive from subsequent WHO technical work and country-level decisions.
WHO described the meeting as advancing the development of the first volume of monographs and as part of an ongoing process that began in November 2024. The source said experts discussed the way forward for further development of the work, but it did not publish timelines, target publication dates, or the complete schedule of future meetings.
Key procedural items remain unresolved in the public account: the source did not report detailed monograph methodologies, criteria for final monograph selection beyond the 12 named priorities, or the mechanisms by which countries will adopt and adapt the standards. Those operational questions are outstanding and will determine how rapidly the publication can move from draft to usable guidance for regulators and health systems.
END OF ARTICLE